Ackermans & van Haaren: Results capping already strong subsidiary reporting. DPS beat. Fagron: Acquisition of Pharmavit Europe, active in nutraceutical raw materials. Fugro: Patience please. Kendrion: Sees signs of improvement in EU economy. Proximus: 2026 dividend halved, 2028-30 targets a bit better on lower capex. Proximus: 4Q25 in line EBITDA on weaker sales, FCF up; 2026 guidance below on EBITDA. Recticel: Strong FY25 results, CEO transition seen as a negative
Proximus is holding a CMD in Brussels today that we are attending. Ahead of that, it has put out a release with FY26, FY28 guidance, and some long-term (FY30) capex and FCF estimates too. We don’t have all the detail yet, but we outline our initial thoughts in this report, and some commentary on the Q4 results too.
Proximus reported solid 4Q25 results, with the underlying EBITDA of € 437m broadly in line with expectations (kbcse: € 433m, css: € 434m) while the FY25 organic FCF of € 130m came in slightly ahead (kbcse: € 107m, css: € 102m). Although the outlook 2026 was broadly in line, we welcome the lower capex spending of between € 1.20- € 1.25bn (kbcse: € 1.30bn, css: € 1.29bn), resulting in a better than expected FCF guidance for 2026 of up to € 100m (kbcse: € 39m, css: € 24m). By 2030, the group expect...
Aalberts: In-line FY25, but low quality / AMG: 4Q25 beat by 7%; in-line 2026 guidance / Bekaert: In-line 2025, cautious outlook for 2026 to result in c.8% consensus cut / CMB.TECH: A small bit beat but not the full story / Corbion: Dividend sweetener / CTP: Q4 results lighter due to some delays; stronger 2026 outlook / DEME: Strong FY25 numbers and FY26 outlook / Elia Group: Preview FY25 results / SBM Offshore: Another step-up in shareholder return / Syensqo: Substantial miss in 4Q25; FY26 outlo...
UCB reported another CSS beat with FY25 revenue of € 7,741m coming in 1.7% above expectations driven by stellar performance from Bimzelx, which generated € 2,227m in sales, 5.8% above expectations. We note that adj. EBITDA and net profit also came in above CSS despite increased investments in sales and marketing. With head to head data for Bimzelx vs. Skyrizi in PsA now expected in 1H26, we continue to view UCB as an attractive name to own, and reiterate our € 284 TP and BUY rating.
A director at Montea NV bought 1,000 shares at 73.740EUR and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Autolus Therapeutics to Participate in Upcoming Investor Conferences LONDON and GAITHERSBURG, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in two upcoming investor conferences. TD Cowen 46th Annual Health Care ConferenceDate and time: March 3, 2028; 11:10am EST / 4:10pm GMTLocation: Boston, MAPresenter: Chief Executive Officer Dr. Christian Itin A webcast of the presentation will ...
CFE: Preview: underlying 2026 margin to improve / DEME: Preview: strong 2025, eyes on 2026 outlook / JDE Peet's: Acquisition by KDP expected to close in 2Q26 / Solvay: 2025 ends with strong FCF; 2026F und. EBITDA guidance slightly below, supported by one-off / UCB: Peer Moonlake investor day / Vastned: Beat on bottom line with operational metrics accelerating, but outlook remains weak
We reiterate our HOLD rating on Ontex and lower our target price from €5.40 to €4.70, following the group's weaker-than-expected FY25 results and a FY26 guidance we see as challenging, especially given the strong headwinds the company will have to cope with over 1H26. Ontex's material exposure to the Baby care segment remains the most challenged one in our view, given unsupportive demographics trends in key markets and material price and promotion pressure from branded players. At €4.7, Ontex wo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.